[go: up one dir, main page]

NO20091588L - Chemical process - Google Patents

Chemical process

Info

Publication number
NO20091588L
NO20091588L NO20091588A NO20091588A NO20091588L NO 20091588 L NO20091588 L NO 20091588L NO 20091588 A NO20091588 A NO 20091588A NO 20091588 A NO20091588 A NO 20091588A NO 20091588 L NO20091588 L NO 20091588L
Authority
NO
Norway
Prior art keywords
preparation
processes
relates
quinazoline derivatives
quinazoline
Prior art date
Application number
NO20091588A
Other languages
Norwegian (no)
Inventor
James Gair Ford
George Joseph Sependa
Euan Alexander Arnott
John Crosby
Matthew Charles Evans
Martin Francis Jones
Kevin William Leslie
Ian Michael Mcfarlane
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20091588L publication Critical patent/NO20091588L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår kjemiske prosesser for fremstilling av visse kinazolinderivater eller farmasøytisk akseptable salter derav. Oppfinnelsen angår også prosesser for fremstilling av visse mellomprodukter anvendelige ved fremstilling av kinazolinderivatene og prosesser for fremstilling av kinazolinderivatene ved å anvende nevnte mellomprodukter. Spesielt angår foreliggende oppfinnelse kjemiske prosesser og mellomprodukter anvendelige for fremstilling av forbindelsen 4-(4-fluor-2-metylindol-5-yloksy)-6-metoksy-7-(3-pyrrolidin-1-ylpropoksy)kinazolin.The present invention relates to chemical processes for the preparation of certain quinazoline derivatives or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of certain intermediates useful in the preparation of the quinazoline derivatives and processes for the preparation of the quinazoline derivatives using said intermediates. In particular, the present invention relates to chemical processes and intermediates useful for the preparation of the compound 4- (4-fluoro-2-methylindol-5-yloxy) -6-methoxy-7- (3-pyrrolidin-1-ylpropoxy) quinazoline.

NO20091588A 2006-11-02 2009-04-22 Chemical process NO20091588L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86403606P 2006-11-02 2006-11-02
US95740107P 2007-08-22 2007-08-22
PCT/GB2007/004176 WO2008053221A2 (en) 2006-11-02 2007-11-01 Process for preparing indol- 5 -oxy- quinazoline derivatives and intermediates

Publications (1)

Publication Number Publication Date
NO20091588L true NO20091588L (en) 2009-05-28

Family

ID=39284186

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091588A NO20091588L (en) 2006-11-02 2009-04-22 Chemical process

Country Status (18)

Country Link
US (2) US7851623B2 (en)
EP (3) EP2540705A3 (en)
JP (1) JP2010508340A (en)
KR (1) KR20090079247A (en)
CN (3) CN101528688B (en)
AR (1) AR063449A1 (en)
AU (1) AU2007315982B2 (en)
BR (1) BRPI0717751A2 (en)
CA (1) CA2667920A1 (en)
CL (1) CL2007003158A1 (en)
IL (1) IL198117A0 (en)
MX (1) MX2009004708A (en)
MY (2) MY150219A (en)
NO (1) NO20091588L (en)
RU (2) RU2012139319A (en)
SG (2) SG176446A1 (en)
TW (1) TW200833667A (en)
WO (1) WO2008053221A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288378B6 (en) 1999-02-10 2016-07-01 Astrazeneca Ab Quinazoline derivates as angiogenesis inhibitors
PT1474420E (en) * 2002-02-01 2012-05-10 Astrazeneca Ab Quinazoline compounds
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
CN102603718B (en) * 2012-02-08 2014-01-29 武汉凯斯瑞科技有限公司 Synthesis method of cediranib
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN103275069B (en) * 2013-05-22 2015-03-11 苏州明锐医药科技有限公司 Preparation method of cediranib
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN107840843A (en) * 2017-10-17 2018-03-27 浙江工业大学义乌科学技术研究院有限公司 A kind of synthetic method of AZD2171 intermediate
JP2024177597A (en) * 2021-11-04 2024-12-20 日産化学株式会社 Method for producing indole compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK288378B6 (en) * 1999-02-10 2016-07-01 Astrazeneca Ab Quinazoline derivates as angiogenesis inhibitors
MXPA03000874A (en) * 2000-08-09 2003-06-06 Astrazeneca Ab Chemical compounds.
PT1474420E (en) * 2002-02-01 2012-05-10 Astrazeneca Ab Quinazoline compounds
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
JP4255057B2 (en) 2003-03-12 2009-04-15 日本カーリット株式会社 Conductivity imparting agent and conductive material
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
JP4676719B2 (en) * 2004-06-04 2011-04-27 富山薬品工業株式会社 Electrolyte for dye-sensitized solar cell and dye-sensitized solar cell using the same
JP2006024785A (en) 2004-07-08 2006-01-26 Tomiyama Pure Chemical Industries Ltd Electric double layer capacitor and nonaqueous electrolytic solution therefor
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
US20110257395A1 (en) 2011-10-20
TW200833667A (en) 2008-08-16
EP2540706A3 (en) 2013-11-06
AR063449A1 (en) 2009-01-28
CN101528688B (en) 2012-09-05
EP2540705A2 (en) 2013-01-02
US8754240B2 (en) 2014-06-17
CN102532108A (en) 2012-07-04
BRPI0717751A2 (en) 2013-10-22
MX2009004708A (en) 2009-05-15
RU2009120567A (en) 2010-12-10
RU2012139318A (en) 2014-03-20
WO2008053221A2 (en) 2008-05-08
RU2012139319A (en) 2014-03-20
JP2010508340A (en) 2010-03-18
CN102584798A (en) 2012-07-18
SG176447A1 (en) 2011-12-29
US7851623B2 (en) 2010-12-14
MY150219A (en) 2013-12-31
CN101528688A (en) 2009-09-09
US20080221322A1 (en) 2008-09-11
MY179610A (en) 2020-11-11
EP2540706A2 (en) 2013-01-02
IL198117A0 (en) 2009-12-24
EP2540705A3 (en) 2013-10-30
CA2667920A1 (en) 2008-05-08
CL2007003158A1 (en) 2008-05-16
AU2007315982A1 (en) 2008-05-08
AU2007315982B2 (en) 2012-07-12
KR20090079247A (en) 2009-07-21
WO2008053221A3 (en) 2008-12-31
SG176446A1 (en) 2011-12-29
EP2129657A2 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
NO20091588L (en) Chemical process
NO20083918L (en) Dihydridiazepines useful as inhibitors of protein kinases
NO20064895L (en) 6,6-Bisyclic ring-substituted heterobicyclic protein kinase inhibitors
NO20090755L (en) Amino-imidazolones and their use as a drug for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia
NO20084747L (en) Tetrahydropteridines useful as inhibitors of protein kinases
NO20070917L (en) Imidazotriazines as protein kinase inhibitors
NO20083669L (en) 4-aryl-2amino-pyrimidines or 4-aryl-2-aminoalkylpyrimidines as jak-2 modulators and methods of use thereof
NO20071619L (en) Process for the preparation of indazole compound
NO20090723L (en) Condensed heterocyclic derivatives and methods of use
NO20081893L (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NO20065727L (en) Pyrrole inhibitors of arch-protein kinase, their synthesis and their intermediates
UA102251C2 (en) Aminidihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
NO20085257L (en) Purinone derivatives as HM74a agonists
DK2358717T3 (en) AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS TREATMENT OR PREVENTION OF DIABETES
NO20083427L (en) Cystotoxic agents comprising novel tomaymycin derivatives and their therapeutic use
NO20090628L (en) Pyridizinone derivatives
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
ATE445593T1 (en) ACETYLENE DERIVATIVES
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
CY1109569T1 (en) Substituted cyclohexane-1,4-diamine derivatives
MY149834A (en) Chemical in situ sulphonating process
ATE481972T1 (en) QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application